Safety and Efficacy of 9 Days Vein-to-Vein Decentralized Manufactured Anti-CD19 CAR T-Cell Therapy for Relapsed/Refractory B-cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Physics

Cancer Oncology

Medicine

Immunology

Internal Medicine

Show all topics

DOI

10.1016/s2152-2650(24)01029-2